Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/50283

TitleA Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours
Author(s)Baruchel, Sylvain
Sharp, Julia R.
Bartels, Ute
Hukin, Juliette
Odame, Isaac
Portwine, Carol
Strother, Doug
Fryer, Chris
Reis, R. M.
Martinho, Olga
KeywordsImatinib
Paediatrics
Phase II
Central nervous system neoplasms
Brain neoplasms
Platelet-derived growth factor alpha receptor
C-kit
Drug toxicity
Pharmacokinetics
Issue dateSep-2009
PublisherElsevier
JournalEuropean Journal of Cancer
Abstract(s)PURPOSE: To evaluate the safety, efficacy and pharmacokinetics of imatinib in children with recurrent or refractory central nervous system (CNS) tumours expressing KIT and/or PDGFRA. METHODS: Nineteen patients aged 2-18 years, with recurrent or refractory CNS tumours expressing either of the target receptors KIT and/or PDGFRA (by immunohistochemistry) were eligible. Participants received imatinib orally at a dose of 440 mg/m(2)/day and toxicities and tumour responses were monitored. Serial blood and cerebrospinal fluid samples for pharmacokinetics were obtained in a subset of consenting patients. Frozen tumour samples were analysed retrospectively for KIT and PDGFRA gene amplification in a subset of patients for whom samples were available. RESULTS: Common toxicities were lymphopaenia, neutropaenia, leucopaenia, elevated serum transaminases and vomiting. No intratumoural haemorrhages were observed. Although there were no objective responses to imatinib, four patients had long-term stable disease (SD) (38-104 weeks). Our results suggest a possible relationship between KIT expression and maintenance of SD with imatinib treatment; KIT immunopositivity was seen in only 58% (11/19) of study participants overall, but in 100% of patients with SD at 38 weeks. All patient tumours showed PDGFRA expression. Pharmacokinetic data showed a high interpatient variability, but corresponded with previously reported values. CONCLUSIONS: Imatinib at 440 mg/m(2)/day is relatively safe in children with recurrent CNS tumours, but induced no objective responses. Demonstration of SD in previously progressing patients (KIT-expressing) suggests cytostatic activity of imatinib.
TypeArticle
URIhttp://hdl.handle.net/1822/50283
DOI10.1016/j.ejca.2009.05.008
ISSN0959-8049
Publisher versionhttps://www.sciencedirect.com/science/article/pii/S0959804909003487
Peer-Reviewedyes
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
baruchel s_ eur j cancer 2009.pdf141,46 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID